Literature DB >> 20889542

L-arginine deprivation regulates cyclin D3 mRNA stability in human T cells by controlling HuR expression.

Paulo C Rodriguez1, Claudia P Hernandez, Kevin Morrow, Rosa Sierra, Jovanny Zabaleta, Dorota D Wyczechowska, Augusto C Ochoa.   

Abstract

Myeloid-derived suppressor cells are a major mechanism of tumor-induced immune suppression in cancer. Arginase I-producing myeloid-derived suppressor cells deplete l-arginine (L-Arg) from the microenvironment, which arrests T cells in the G(0)-G(1) phase of the cell cycle. This cell cycle arrest correlated with an inability to increase cyclin D3 expression resulting from a decreased mRNA stability and an impaired translation. We sought to determine the mechanisms leading to a decreased cyclin D3 mRNA stability in activated T cells cultured in medium deprived of L-Arg. Results show that cyclin D3 mRNA instability induced by L-Arg deprivation is dependent on response elements found in its 3'-untranslated region (UTR). RNA-binding protein HuR was found to be increased in T cells cultured in medium with L-Arg and bound to the 3'-untranslated region of cyclin D3 mRNA in vitro and endogenously in activated T cells. Silencing of HuR expression significantly impaired cyclin D3 mRNA stability. L-Arg deprivation inhibited the expression of HuR through a global arrest in de novo protein synthesis, but it did not affect its mRNA expression. This alteration is dependent on the expression of the amino acid starvation sensor general control nonderepressible 2 kinase. These data contribute to an understanding of a central mechanism by which diseases characterized by increased arginase I production may cause T cell dysfunction.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20889542      PMCID: PMC3108892          DOI: 10.4049/jimmunol.1001224

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  30 in total

1.  HuA and tristetraprolin are induced following T cell activation and display distinct but overlapping RNA binding specificities.

Authors:  A Raghavan; R L Robison; J McNabb; C R Miller; D A Williams; P R Bohjanen
Journal:  J Biol Chem       Date:  2001-10-15       Impact factor: 5.157

Review 2.  Post-transcriptional regulation of gene expression by degradation of messenger RNAs.

Authors:  Annamaria Bevilacqua; Maria Cristina Ceriani; Sergio Capaccioli; Angelo Nicolin
Journal:  J Cell Physiol       Date:  2003-06       Impact factor: 6.384

3.  Small interfering RNA-mediated gene silencing in T lymphocytes.

Authors:  Michael T McManus; Brian B Haines; Christopher P Dillon; Charles E Whitehurst; Luk van Parijs; Jianzhu Chen; Phillip A Sharp
Journal:  J Immunol       Date:  2002-11-15       Impact factor: 5.422

4.  Selective degradation of AU-rich mRNAs promoted by the p37 AUF1 protein isoform.

Authors:  Bedabrata Sarkar; Qiaoran Xi; Cheng He; Robert J Schneider
Journal:  Mol Cell Biol       Date:  2003-09       Impact factor: 4.272

5.  Regulation of T cell receptor CD3zeta chain expression by L-arginine.

Authors:  Paulo C Rodriguez; Arnold H Zea; Kirk S Culotta; Jovanny Zabaleta; Juan B Ochoa; Augusto C Ochoa
Journal:  J Biol Chem       Date:  2002-04-11       Impact factor: 5.157

6.  L-arginine consumption by macrophages modulates the expression of CD3 zeta chain in T lymphocytes.

Authors:  Paulo C Rodriguez; Arnold H Zea; Joanna DeSalvo; Kirk S Culotta; Jovanny Zabaleta; David G Quiceno; Juan B Ochoa; Augusto C Ochoa
Journal:  J Immunol       Date:  2003-08-01       Impact factor: 5.422

Review 7.  Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives.

Authors:  Paulo C Rodríguez; Augusto C Ochoa
Journal:  Immunol Rev       Date:  2008-04       Impact factor: 12.988

8.  Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes.

Authors:  Paulo C Rodriguez; Marc S Ernstoff; Claudia Hernandez; Michael Atkins; Jovanny Zabaleta; Rosa Sierra; Augusto C Ochoa
Journal:  Cancer Res       Date:  2009-02-05       Impact factor: 12.701

9.  Requirement for cyclin D3 in lymphocyte development and T cell leukemias.

Authors:  Ewa Sicinska; Iannis Aifantis; Laurent Le Cam; Wojciech Swat; Christine Borowski; Qunyan Yu; Adolfo A Ferrando; Steven D Levin; Yan Geng; Harald von Boehmer; Piotr Sicinski
Journal:  Cancer Cell       Date:  2003-12       Impact factor: 31.743

10.  Nutritional control of mRNA stability is mediated by a conserved AU-rich element that binds the cytoplasmic shuttling protein HuR.

Authors:  Ibrahim Yaman; James Fernandez; Bedabrata Sarkar; Robert J Schneider; Martin D Snider; Laura E Nagy; Maria Hatzoglou
Journal:  J Biol Chem       Date:  2002-08-23       Impact factor: 5.157

View more
  37 in total

1.  Cyclin D3: To translate or not to translate.

Authors:  J Alan Diehl
Journal:  Cell Cycle       Date:  2016-08-11       Impact factor: 4.534

Review 2.  Energy metabolic pathways control the fate and function of myeloid immune cells.

Authors:  Amir A Al-Khami; Paulo C Rodriguez; Augusto C Ochoa
Journal:  J Leukoc Biol       Date:  2017-05-17       Impact factor: 4.962

3.  Tadalafil augments tumor specific immunity in patients with head and neck squamous cell carcinoma.

Authors:  Joseph A Califano; Zubair Khan; Kimberly A Noonan; Lakshmi Rudraraju; Zhe Zhang; Hao Wang; Steven Goodman; Christine G Gourin; Patrick K Ha; Carole Fakhry; John Saunders; Marshall Levine; Mei Tang; Geoffrey Neuner; Jeremy D Richmon; Ray Blanco; Nishant Agrawal; Wayne M Koch; Shanthi Marur; Donald T Weed; Paolo Serafini; Ivan Borrello
Journal:  Clin Cancer Res       Date:  2015-01-01       Impact factor: 12.531

4.  Lymphocyte lineage-specific and developmental stage specific mechanisms suppress cyclin D3 expression in response to DNA double strand breaks.

Authors:  Amy DeMicco; Tyler Reich; Rahul Arya; Adrian Rivera-Reyes; Megan R Fisher; Craig H Bassing
Journal:  Cell Cycle       Date:  2016-06-21       Impact factor: 4.534

5.  l-Arginine depletion blunts antitumor T-cell responses by inducing myeloid-derived suppressor cells.

Authors:  Matthew Fletcher; Maria E Ramirez; Rosa A Sierra; Patrick Raber; Paul Thevenot; Amir A Al-Khami; Dulfary Sanchez-Pino; Claudia Hernandez; Dorota D Wyczechowska; Augusto C Ochoa; Paulo C Rodriguez
Journal:  Cancer Res       Date:  2014-11-18       Impact factor: 12.701

Review 6.  Arginases and arginine deficiency syndromes.

Authors:  Sidney M Morris
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2012-01       Impact factor: 4.294

7.  Lipid Metabolism in Tumor-Associated Myeloid-Derived Suppressor Cells.

Authors:  Wei Liu; Hua Song; Xiaojing Li; Deshan Ren; Shuai Ding; Yan Li
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 8.  Metabolism of L-arginine by myeloid-derived suppressor cells in cancer: mechanisms of T cell suppression and therapeutic perspectives.

Authors:  Patrick Raber; Augusto C Ochoa; Paulo C Rodríguez
Journal:  Immunol Invest       Date:  2012       Impact factor: 3.657

9.  Increased accumulation of regulatory granulocytic myeloid cells in mannose receptor C type 1-deficient mice correlates with protection in a mouse model of neurocysticercosis.

Authors:  Pramod Kumar Mishra; Elizabeth G Morris; Jenny A Garcia; Astrid E Cardona; Judy M Teale
Journal:  Infect Immun       Date:  2013-01-14       Impact factor: 3.441

Review 10.  Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment.

Authors:  Katherine H Parker; Daniel W Beury; Suzanne Ostrand-Rosenberg
Journal:  Adv Cancer Res       Date:  2015-05-12       Impact factor: 6.242

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.